UTILIZATION STUDY OF DABIGATRAN ETEXILATE IN HOSPITALIZED PATIENTS

被引：0

作者：

Lopez Isabel, Cuesta ^{[1
]}

Silveira Eva, Delgado ^{[1
]}

Vicedo Teresa, Bermejo ^{[1
]}

Gonzalez Juana, Benedi ^{[1
]}

机构：

[1] Univ Complutense Madrid, Dept Farmacol, E-28040 Madrid, Spain

来源：

ATENCION FARMACEUTICA | 2012年 / 14卷 / 03期

关键词：

DABIGATRAN ETEXILATE; UTILIZATION STUDY; THROMBOEMBOLISM; VENOUS; SURGICAL PATIENT; PROPHYLAXIS; TOTAL KNEE REPLACEMENT; TOTAL HIP-REPLACEMENT; VENOUS THROMBOEMBOLISM; ORAL ANTICOAGULANTS; PREVENTION; RIVAROXABAN; ENOXAPARIN; TRIAL;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Objective: To define the utilization profile of dabigatran etexilate in hospitalized patients. Method: Four-month observational prospective utilization study of the type prescription-indication. Data were obtained from pharmacological treatments of the electronic prescribing program, analytics and patients' clinical records. We reviewed their adaptation to the drug's data sheet and the hospital's utilization protocol. We recorded any adverse drug reactions. Results: 138 patients began treatment with dabigatran etexilate. In 89.13% of patients, dabigatran was prescribed for the approved indication in the data sheet, while in 10.87% it was used for other indications. 57.24% of prescriptions were adapted to the hospital's protocol and the data sheet. Conclusion: The use of dabigatran has been adequate for the majority of patients.

引用

页码：174 / 178

页数：5

共 50 条

[21] Dabigatran Etexilate: A Novel Oral Thrombin Inhibitor for Thromboembolic Disease
Bovio, Jessica A.
Smith, Steven M.
Gums, John G.
ANNALS OF PHARMACOTHERAPY, 2011, 45 (05) : 603 - 614
[22] The discovery of dabigatran etexilate for the treatment of venous thrombosis
Feuring, Martin
van Ryn, Joanne
EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (07) : 717 - 731
[23] Dabigatran Etexilate A New Oral Thrombin Inhibitor
Hankey, Graeme J.
Eikelboom, John W.
CIRCULATION, 2011, 123 (13) : 1436 - 1450
[24] Incidence and Management of Ischemic Stroke and Intracerebral Hemorrhage in Patients on Dabigatran Etexilate Treatment
Watanabe, Masaki
Siddiqui, Fazeel M.
Qureshi, Adnan I.
NEUROCRITICAL CARE, 2012, 16 (01) : 203 - 209
[25] Oral bioavailability of dabigatran etexilate (Pradaxa®) after co-medication with verapamil in healthy subjects
Haertter, Sebastian
Sennewald, Regina
Nehmiz, Gerhard
Reilly, Paul
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (04) : 1053 - 1062
[26] Economic Evaluation of Dabigatran Etexilate for the Prevention of Venous Thromboembolism After Total Knee and Hip Replacement Surgery
Wolowacz, Sorrel E.
Roskell, Neil S.
Maciver, Fiona
Beard, Stephen M.
Robinson, Paul A.
Plumb, Jonathan M.
Dolan, Gerry
Brenkel, Ivan J.
CLINICAL THERAPEUTICS, 2009, 31 (01) : 194 - 212
[27] Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery
Wolowacz, Sorrel E.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2011, 11 (01) : 9 - 25
[28] Dabigatran Etexilate: An Oral Direct Thrombin Inhibitor for the Management of Thromboembolic Disorders
Cheng, Judy W. M.
Vu, Huyen
CLINICAL THERAPEUTICS, 2012, 34 (04) : 766 - 787
[29] A comparison of apixaban and dabigatran etexilate for thromboprophylaxis following hip and knee replacement surgery
Mayer, Adriane
Schuster, Philipp
Fink, Bernd
ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY, 2017, 137 (06) : 797 - 803
[30] Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin
Haertter, Sebastian
Koenen-Bergmann, Michael
Sharma, Ashish
Nehmiz, Gerhard
Lemke, Ute
Timmer, Wolfgang
Reilly, Paul A.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 74 (03) : 490 - 500

← 1 2 3 4 5 →